Synthetic biology tools for novel secondary metabolite discovery in streptomyces by Lee, Namil et al.
 
 
General rights 
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright 
owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. 
 
 Users may download and print one copy of any publication from the public portal for the purpose of private study or research. 
 You may not further distribute the material or use it for any profit-making activity or commercial gain 
 You may freely distribute the URL identifying the publication in the public portal 
 
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately 
and investigate your claim. 
  
 
   
 
 
Downloaded from orbit.dtu.dk on: Sep 11, 2019
Synthetic biology tools for novel secondary metabolite discovery in streptomyces
Lee, Namil; Hwang, Soonkyu; Lee, Yongjae; Cho, Suhyung; Palsson, Bernhard
Published in:
Journal of Microbiology and Biotechnology
Link to article, DOI:
10.4014/jmb.1904.04015
Publication date:
2019
Document Version
Publisher's PDF, also known as Version of record
Link back to DTU Orbit
Citation (APA):
Lee, N., Hwang, S., Lee, Y., Cho, S., & Palsson, B. (2019). Synthetic biology tools for novel secondary
metabolite discovery in streptomyces. Journal of Microbiology and Biotechnology, 29(5), 667-686.
https://doi.org/10.4014/jmb.1904.04015
May 2019⎪Vol. 29⎪No. 5
J. Microbiol. Biotechnol. (2019), 29(5), 667–686
https://doi.org/10.4014/jmb.1904.04015 Research Article jmbReview
Synthetic Biology Tools for Novel Secondary Metabolite Discovery in
Streptomyces
Namil Lee1, Soonkyu Hwang1, Yongjae Lee1, Suhyung Cho1, Bernhard Palsson3,4,5, and Byung-Kwan Cho1,2*
1Department of Biological Sciences and KI for the BioCentury, Korea Advanced Institute of Science and Technology, Daejeon 34141, Republic
of Korea
2Intelligent Synthetic Biology Center, Daejeon 34141, Republic of Korea
3Department of Bioengineering, University of California San Diego, La Jolla, CA, 92093, USA
4Department of Pediatrics, University of California San Diego, La Jolla, CA, 92093, USA
5Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, Lyngby, 2800, Denmark
Introduction
Streptomyces species are Gram-positive bacteria that
produce more than two-thirds of the medically and
agriculturally important secondary metabolites, including
antibiotic, anticancer, antifungal, antiparasitic, and immuno-
suppressive compounds [1, 2]. Recent genome sequencing
efforts have revealed that individual Streptomyces species
have a wealth of genetic potential to produce novel
secondary metabolites. However, most secondary metabolite
biosynthetic gene clusters (SM-BGCs) are silent under
laboratory culture conditions, limiting effective use of
Streptomyces [3]. Therefore, activation of silent SM-BGCs is
one of the most promising approaches to discover novel
bioactive secondary metabolites from Streptomyces.
To activate silent SM-BGCs, various strategies have been
applied, including culture media modifications, chemical
or antibiotic treatments, heterologous gene expression in
different hosts, and co-culture with cohabiting microbes
[4]. However, these methods are untargeted, resulting in
non-directed activation of silent SM-BGCs in Streptomyces.
To overcome this limitation, a synthetic biology approach
has been proposed to redesign and reconstruct target SM-
BGCs [5, 6]. Generally, a main obstacle in activating cryptic
SM-BGCs is the difficulty in bypassing the complex native
regulation. Expression of SM-BGCs is tightly governed by
multi-layered regulatory networks, which are often
triggered by environmental signals [7]. Using synthetic
genetic parts, such as promoters, ribosome binding sites
(RBS), and terminators, which are not controlled by the
Received: April 10, 2019
Revised: May 9, 2019
Accepted: May 11, 2019
First published online
May 12, 2019
*Corresponding author
Phone: +82-42-350-2620;
Fax: +82-42-350-5620;
E-mail: bcho@kaist.ac.kr
pISSN 1017-7825, eISSN 1738-8872
Copyright© 2019 by
The Korean Society for Microbiology 
and Biotechnology
Streptomyces are attractive microbial cell factories that have industrial capability to produce a
wide array of bioactive secondary metabolites. However, the genetic potential of the
Streptomyces species has not been fully utilized because most of their secondary metabolite
biosynthetic gene clusters (SM-BGCs) are silent under laboratory culture conditions. In an
effort to activate SM-BGCs encoded in Streptomyces genomes, synthetic biology has emerged
as a robust strategy to understand, design, and engineer the biosynthetic capability of
Streptomyces secondary metabolites. In this regard, diverse synthetic biology tools have been
developed for Streptomyces species with technical advances in DNA synthesis, sequencing, and
editing. Here, we review recent progress in the development of synthetic biology tools for the
production of novel secondary metabolites in Streptomyces, including genomic elements and
genome engineering tools for Streptomyces, the heterologous gene expression strategy of
designed biosynthetic gene clusters in the Streptomyces chassis strain, and future directions to
expand diversity of novel secondary metabolites.
Keywords: Streptomyces, secondary metabolites, biosynthetic gene cluster, antibiotics, synthetic
biology, genome editing, CRISPR/Cas9, heterologous expression
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host’s regulatory system, expression of target SM-BGC can
be achieved through bypassing the native regulatory
networks. In this respect, various synthetic genetic parts
and genome engineering tools are required to regulate gene
expression and redesign target SM-BGCs in Streptomyces.
Even though high GC content and highly interconnected
regulatory networks challenge the application of synthetic
genetic parts that are widely used in other bacterial
Fig. 1. Overview of synthetic biology strategy to produce novel secondary metabolite from Streptomyces. 
Abbreviations: BGC, biosynthetic gene cluster; CDS, coding sequence; 5’ UTR, 5’ untranslated region; RBS, ribosome binding site; WT, wild type;
LA, left homology arm; RA, right homology arm.
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systems to Streptomyces, enabling synthetic biology tools
have been recently developed for Streptomyces engineering
[8]. Here, we review synthetic biology strategies applied in
the discovery of novel secondary metabolites in Streptomyces.
As synthetic biology is defined by an iterative “design-
build-test” cycle in engineering biology, we have classified
the strategy into three steps (Fig. 1). First, for the design
step, discovery of novel SM-BGCs via genome mining is
described, followed by designing of SM-BGCs using
various synthetic genetic parts developed for Streptomyces.
Second, for the build step, the process of building the re-
designed SM-BGCs is discussed, including genome
engineering of original host and SM-BGC assembly into
plasmids for heterologous expression. Further, Streptomyces
chassis strains are suggested as optimal heterologous
expression hosts for reconstructing target SM-BGCs. Third,
for the test step, high-throughput testing methods are
described to measure activation of target SM-BGCs for the
next “design-build-test” cycle.
Mining of Secondary Metabolite Biosynthetic
Gene Clusters 
In the pre-genome mining era, most of the secondary
metabolites in Streptomyces were discovered via chemistry-
based methods of changing culture conditions and mass
spectrometry or NMR biosynthetic identification [9]. Due
to the biochemical complexity of SM-BGCs, however, the
discovery of novel secondary metabolites has been
challenging. This limitation has been overcome through a
genome mining approach, in which recent advances in
DNA sequencing technology caused a rapid increase in the
number of high-quality Streptomyces genome sequences
[10, 11]. To date, about 500 scaffold-level and 84 complete-
level genome sequences of Streptomyces strains are
available in the NCBI database. These large numbers of
genome sequences encode invaluable resources for novel
secondary metabolite discovery [12]. To identify SM-BGCs
from these genome sequences, several genome-mining tools
have been developed, such as ClustSCAN, NP.searcher,
GNP/PRISM, and antiSMASH [13-16]. Among them,
antiSMASH is the most comprehensive and widely used
software pipeline for genome mining, offering a user-
friendly web interface and prediction of the broad
spectrum of SM-BGCs [16]. antiSMASH has detected 45
different classes of SM-BGCs based on a rule-based cluster
detection approach and further predicted the modular
domain structures of genes within these SM-BGCs [17]. 
In general, each Streptomyces genome encodes approxi-
mately 30 SM-BGCs, which are diverse and differ between
species, indicating that Streptomyces strains are an
immeasurable source of novel secondary metabolites [18-
20]. Information about SM-BGCs mined from genome
sequences is not only essential data for novel secondary
metabolite discovery, but also a resource to facilitate
rational design of SM-BGCs based on the synthetic biology
approach. In particular, polyketides (PK) and nonribosomal
peptides (NRP) can be redesigned using this approach as
they are synthesized by serially connected modular
enzymes that recognize module-specific CoAs or amino
acids, respectively [21]. For example, replacement of
AveA1 and module 7 of AveA3 in avermectin BGC of
Streptomyces avermitilis with MilA1 and MilA3 in milbemycin
BGC of S. hygroscopicus resulted in milbemycin production
in S. avermitilis [22]. Taken together, a genome mining
approach can accelerate secondary metabolite discovery at
an unprecedented rate with an ever-growing number of
Streptomyces genome sequences.
Genetic Parts for Streptomyces Synthetic Biology
Genomic information on Streptomyces strains has revealed
the great potential of Streptomyces to produce novel
secondary metabolites. However, most SM-BGCs in
Streptomyces are inactive under general laboratory culture
conditions. For example, although S. coelicolor, S. griseus,
and S. avermitilis genomes encode more than 30 SM-BGCs,
respectively, only 3–5 secondary metabolites have been
detected [1, 11, 23]. Although many efforts have been made
to activate silent SM-BGCs in Streptomyces strains, including
the One Strain-Many Compounds (OSMAC) strategy and
co-cultivation methods [24, 25], these approaches resulted
in non-directed activation of silent BGCs. For specific
activation of targeted SM-BGCs, the following methods
have been implemented: (1) promoter replacement, (2)
overexpression or repression of regulatory genes, (3)
heterologous expression in different hosts, and (4)
refactoring of targeted SM-BGCs [26]. To this end, the
number of genetic parts, such as promoters, ribosome-
binding sites (RBS), and terminators available for
Streptomyces species, has dramatically increased as
summarized in Table 1.
Genetic Parts for Transcriptional Regulation in Streptomyces
In bacterial cells, a transcription unit is defined as a basic
unit of regulation and is composed of several genes and
accessory genetic elements, including promoters, transcrip-
tion start sites (TSS), RBSs, and terminators. Design and
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utilization of these genetic parts, at appropriate strengths,
is critical for precise transcriptional and translational
regulation of targeted gene expression. In transcriptional
regulation, the most important genetic part is the promoter,
which is the binding site of RNA polymerase to initiate
transcription. However, widely used promoters for bacterial
genetic engineering, such as lacZ and T7 promoters, are not
directly applicable in Streptomyces [27, 28], thus only a few
promoters have been used for gene expression in Streptomyces.
The terminator is also important in preventing transcriptional
read-through to downstream genes [29]. Particularly, when
redesigning SM-BGCs in Streptomyces, due to their operon-
like genomic structure, precise transcriptional termination
is required between transcription units. In this section, we
described genetic parts that have been developed and used
to regulate the transcription of Streptomyces.
First, constitutive promoters, which generate constant
gene expression levels regardless of growth phases, are
extensively used for SM-BGC expression in Streptomyces. In
particular, ermE* promoter is the most commonly used
Table 1. Genetic parts for Streptomyces. 
Genetic parts Feature Reference
Constitutive promoters
 ermE* promoter Mutation at the promoter of the erythromycin resistance gene of Streptomyces erythraeus [31]
 SF14P promoter Genome of Streptomyces ghanaensis phage I19 [34]
 kasOP promoter Promoter of SARP family regulator in Stretpomyces coelicolor A3 [33]
 gapdh promoter Promoter of glyceraldehyde-3-phosphate dehydrogenase in Streptomyces griseus [35]
 rpsL promoter Promoter of 30S ribosomal protein S12 in Streptomyces griseus [35]
 195 native or synthetic promoters High-throughput screening in S. venezueale [58]
 32 native promoters Transcriptome data-based selection in S. albus [38]
 166 native promoters Transcriptome data-based selection in S. coelicolor [39]
 2 native promoters Multi-omics data-based selection in S. coelicolor [59]
Inducible promoters
 tipA promoter Thiostrepton-induced promoter [40]
 nitA promoter ε-caprolactam-induced promoter [45]
 xylA promoter Xylose-induced promoter [46]
 tcp830 Tetracycline-induced promoter [43]
 PA3-rolO Resorcinol-induced promoter [44]
 P21-cmt Cumate-induced promoter [44]
Terminators
 Fd Bidirectional transcription termination originated from E. coli phage fd [48]
 TD1 Bidirectional transcription termination originated from Bacillus subtilis phage Φ29 [49]
RBS
 AAAGGAGG Typical RBS sequence of S. coelicolor [134]
 192 native or synthetic RBSs High-throughput screening in S. venezueale [58]
 4 native RBSs Multi-omics data-based selection in S. coelicolor [59]
Reporter genes
 luxAB cassette n-Decanal as substrate; absorbance at 490 nm wavelength [61]
 amy gene Soluble starch with 3,5-dinitrosalycilic acid (DNS) as substrate; absorbance at 540 nm wavelength [64]
 xylE gene Catecol as substrate; absorbance at 375 nm wavelength [62]
 gusA gene p-Nitrophenyl-β-D-glucuronide as substrate; absorbance at 415 nm wavelength [63]
 eGFP Green fluorescent protein; excitation wavelength 470-490 nm and emission wavelength 515 nm [65]
 sfGFP Green fluorescent protein; excitation wavelength 488 nm and emission wavelength 500~550 nm [58]
 mRFP Red fluorescent protein; excitation wavelength 584 nm and emission wavelength 607 nm [67]
 mCherry Red fluorescent protein; excitation wavelength 587 nm and emission wavelength 610 nm [68]
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strong constitutive promoter in Streptomyces, which is a
derivative of the ermE promoter, containing a trinucleotide
deletion in the ermEp1 region of the erythromycin
resistance gene in S. erythraeus [30-32]. Further, SF14P and
kasOP, discovered from the S. ghanaensis phage I19 genome
and promoter of the SARP family regulator in S. coelicolor
A3, respectively, constitutively transcribe gene expression
similarly or more strongly than the ermE* promoter [33, 34].
Additionally, two strong constitutive promoters, gapdhP
and rpsLP, which have higher activity than the ermE*
promoter, were obtained from the promoter region of
housekeeping genes in the S. griseus genome [35]. In
addition, several strategies have been applied to develop
strong constitutive promoters. One approach screens
strong synthetic promoters from a randomized promoter
library. For example, the randomized sequence library of
the kasO promoter was used to generate synthetic
promoters with promoter strength ranging from 0.95% to
187.5%, compared to the parental kasO promoter [33].
Similar approaches have been conducted on the ermE and
actII-orf4 promoters of S. coelicolor [36]. Several strong
promoters were screened through this approach; however,
all promoters were weaker than the ermE* promoter [37].
Another rational strategy identifies strong promoters using
gene expression data. In S. albus, promoter sequences of
highly expressed genes were selected based on transcrip-
tional profiling data, and the strength of each promoter
was tested, resulting in the selection of ten promoters that
were stronger than the ermE* promoter [38]. A similar
study was performed on S. coelicolor, which identified 166
potentially constitutive promoters across the Streptomyces
genus [39].
Second, expression of SM-BGC genes under constitutive
promoters sometimes causes growth retardation. Therefore,
it is desirable to establish a controllable gene expression
system in Streptomyces. To date, the most widely used
inducible promoter in Streptomyces is the tipA promoter,
which is induced by thiostrepton treatment [40, 41]. The
basal expression level of the tipA promoter is considerable,
which limits precise regulation of the targeted gene
expression. However, basal expression of the tipA promoter
is sometimes used to maintain low expression levels of
toxic genes [42]. The tetracycline-induced strong promoter,
tcp830, was constructed by combining conserved sequences
of the ermE promoter and Tn10 tetR/tetO systems [43].
However, like tipA promoter, a major disadvantage of this
promoter is its basal expression level. To overcome this
limitation, inducible promoters with low leaky expression,
such as PA3-rolO and P21-cmt promoters, have been
synthesized. The PA3-rolO promoter is a resorcinol-induced
promoter synthesized by combining the rolO operator and
synthetic promoter PA3. The P21-cmt promoter is a cumate-
induced expression system synthesized by fusing the
operator of the Pseudomonas putida F1 cumate degradation
operon to the P21 synthetic promoter [44]. Other inducible
systems used in Streptomyces are nitA and xylA promoters.
The nitA promoter, which originates from the nitrilase
promoter of Rhodococcus rhodochrous, is induced by a
complex of ε-caprolactam and the transcription regulator
NitR [45]. The recently developed xylA promoter is a
strictly regulated xylose-induced expression promoter [46].
Additionally, several glycerol-inducible systems have been
developed for Streptomyces; however, these systems have
not been utilized because glycerol treatment may alter
intrinsic cellular metabolism [47]. 
Further, only a limited number of terminator sequences
is available in Streptomyces strains. Two bidirectional
transcription terminators, Fd originated from Escherichia
coli phage fd and TD1 originated from Bacillus subtilis
phage ϕ29, are efficiently recognized in Streptomyces [48,
49]. Although lambda T0 and T7 terminators have been
used in several Streptomyces vectors, these terminators have
not been systematically validated in Streptomyces for their
effects on gene expression levels [50]. While most studies
have focused on promoter strength as a determinant of
gene expression levels, transcription terminators also have
crucial roles in recycling transcription complexes and
ultimately gene expression level [51, 52]. To expand the
repertoire of transcription terminators in Streptomyces,
understanding transcription termination and identifying
native terminator sequences in Streptomyces are required.
In this regard, Term-seq, which is a recent RNA sequencing
method that enables genome-wide determination of
transcript 3’ end positions, is a suitable technique for
screening terminator sequences in Streptomyces genomes
[53]. 
Taken together, many efforts in molecular biology of
Streptomyces have provided genetic parts to control gene
expression, including constitutive promoters, inducible
promoters, and terminators. However, to flexibly and
precisely control secondary metabolite production in
Streptomyces, more generalized and validated genetic parts
for transcription, which can be used in various Streptomyces
species and at different strengths, have to be developed.
Genetic Parts for Translational Regulation in Streptomyces
Because cellular protein level does not directly correlate
with mRNA abundance, yet depends on translational
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efficiency, transcriptional regulation alone is not sufficient
to design an efficient gene expression system in Streptomyces
[54, 55]. Translational efficiency is primarily determined by
5’ untranslated regions (5’-UTR), RBS, and codon usage of
target genes [56]. For example, the RBS contains the Shine
Dalgarno (SD) sequence, which includes a complementary
sequence with the 3’ end of the 16s rRNA region of the 30S
ribosomal subunit. Sequence diversity and accessibility of
the SD sequence influence binding affinity with the
ribosome, determining translational efficiency [57]. In this
regard, several studies have measured the strength of the
5’-UTR and RBS in Streptomyces species to expand genetic
parts for Streptomyces engineering. In this section, we will
provide two examples of translational regulatory genetic
part screenings in Streptomyces genomes.
First, in S. venezuelae, sequences of the strongest RBS
among 15 native RBSs were selected and randomized.
After comparing the RBS strength, 177 synthetic RBSs with
activity over 200-fold compared to their parental RBSs were
collected. Furthermore, seven promoters were combined
with nine RBSs in a pairwise manner to screen the most
optimal promoter-RBS set for gene expression [58]. Second,
two promoters and four 5’-UTR sequences were selected
from S. coelicolor based on multi-omics data, including TSS-
seq, RNA-seq, and Ribo-seq. Pairwise sets of promoters
and 5’-UTR sequences showed strength in a range of 0.03-
to 2.4-fold, compared to the ermE* promoter with the SD
sequence of the nitA gene [59]. Although development of a
translational regulatory genetic part is at the beginning
stage, as compared to transcription, ultimately transcriptional
and translational genetic parts with various strengths have
to be combined and utilized to design and control enzyme
stoichiometry in SM-BGCs for enhancing secondary
metabolite production.
Reporter Systems for High-Throughput Screening 
For high-throughput characterization of genetic parts
developed for Streptomyces, reporter systems that rapidly
represent gene expression level with minimal influence to
the cell physiology are required. Although many antibiotic
resistance genes have been used as conventional markers
for gene expression, their effects on cellular metabolism
and narrow dynamic range limit their suitability for gene
expression quantification [32, 60]. To quantify gene
expression, colorimetric methods are more appropriate
because gene expression levels can be quantified by
measuring the absorbance of a specific wavelength of light.
To date, various colorimetric methods, including luxAB,
amy, xylE, and gusA, have been employed in Streptomyces
strains [61-64]. In particular, gusA is the most widely used
colorimetric reporter system in Streptomyces strains [44, 59].
However, colorimetric reporter systems are based on an
enzymatic reaction that requires an additional substrate
treatment, which may affect cellular metabolism (Table 1).
For example, catechol dioxygenase, encoded by xylE,
produces hydroxymuconic semialdehyde with a yellow color
from catechol as a substrate [62]. In contrast, fluorescent
proteins do not require any supplemental reagents and
thus are suitable for high-throughput screening using
fluorescence-activated cell sorting (FACS). However, since
Streptomyces have relatively high levels of autofluorescence,
several studies have argued that fluorescent proteins are
not appropriate for high-throughput screening of Streptomyces
strains [63]. Despite this limitation, several efforts have
been made to apply fluorescent proteins in Streptomyces
[65]. Among the fluorescent proteins, GFP derivatives,
such as eGFP and sfGFP, are widely used in Streptomyces,
and mRFP has been implemented to enable multi-color
fluorescence-based studies [58, 65-67]. To test the available
fluorescent proteins in S. venezuelae, seven fluorescent
proteins (mTagBFP, mCerulean, mTFP, sfGFP, mCherry,
mKate, and mCardinal) were expressed, and the fluorescence
intensity of each fluorescent protein was compared. Among
the seven fluorescent proteins, mCherry protein showed
the most significant reduction in signal-to-background
noise level and was used for further studies to characterize
genetic parts of S. venezuelae [68]. 
CRISPR/Cas-Based Genome-Engineering Tools
for Streptomyces
To utilize genetic parts and reconstruct metabolic pathways
for secondary metabolite production, efficient genome
engineering tools are required. Conventional genome
engineering of Streptomyces is heavily dependent on either
single or double crossover of a plasmid, which is laborious
and time-consuming to obtain the desired clones [32].
Furthermor, the use of selection markers, such as
antibiotics resistance genes, is often required to avoid
reversion of the engineered genotype to wild type and may
confer undesired effects, including polar effects. To
overcome this limitation, site-specific recombination
strategies, including Cre/loxP, Dre/rox and Flp/FRT, have
been exploited in Streptomyces [69-72]. However, these
approaches retain recombinase recognition sites in the
chromosome and may limit successive applications for
multiple genetic manipulations. 
Recently, CRISPR/Cas9 (clustered regularly interspaced
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short palindromic repeats and CRISPR-associated protein
9) has emerged as a promising tool for genome engineering
of Streptomyces strains [50, 73-78]. Briefly, the Cas9 endo-
nuclease forms a complex with guide RNA (gRNA) and is
guided to a protospacer sequence, which is complementary
to a spacer sequence of gRNA [79]. The guided Cas9 induces
a double-strand break (DSB) in the genome, followed by
repairing the DSB via native non-homologous end joining
repair (NHEJ) or homology directed repair (HDR) mecha-
nisms which facilitate genome engineering. CRISPR/Cas9
systems are superior to simple homologous recombination
or site-specific recombination systems as they facilitate
unmarked genome engineering with reduced time and
labor. Even though other genome engineering strategies,
such as zinc finger nuclease and transcription activator-like
effector nuclease, have been developed, the protein-
mediated recognition of target DNA sequence requires design
of appropriate proteins for individual target sequences and
thus limits their applications [80-82]. Therefore, the CRISPR/
Cas9 system has become a dominant genome engineering
tool, outpacing their performance (Table 2) [83].
Editing Streptomyces Genomes and Secondary Metabolite
Biosynthetic Gene Clusters
The DSB by Cas9 occurs only if a specific sequence motif,
called a protospacer adjacent motif (PAM), is present next
to the protospacer [84]. All applications of the CRISPR/
Cas9 system in Streptomyces strains utilize Cas9 from
Streptococcus pyogenes (SpCas9), whose cognate PAM
sequence is 5’-NGG [85]. As a large portion of Streptomyces
genome is typically composed of G and C, SpCas9 offers
plenty of potential target sites for CRISPR/Cas9-based
genome engineering. Using the CRISPR/Cas9 system,
genetic manipulations, including deletion, insertion, and
point mutation, have been executed in various Streptomyces
species [18, 42, 50, 86-94]. 
CRISPR/Cas9-based approaches can be divided by the
type of DSB repair, NHEJ and HDR. NHEJ-mediated
genome engineering generates random mutation, insertion
or deletion of a few nucleotides, to disrupt a gene of interest
[86, 88, 93]. Further, it has been applied to S. coelicolor and
S. rimosus to disrupt actinorhodin synthesis and the
pentose phosphate pathway, respectively. However, this
technology was inefficient since the NHEJ system of most
Streptomyces species is incomplete [86]. To enhance NHEJ-
based genome engineering efficiency, LigD, the lacking
component of NHEJ, was simultaneously introduced into
S. coelicolor with CRISPR/Cas9 [86]. However, to avoid this
limitation, CRISPR/Cas9-mediated genome engineering
approaches in Streptomyces utilize HDR. For HDR-mediated
genome engineering, template DNA for homologous
recombination is introduced with CRISPR/Cas9 to enhance
production of secondary metabolites and activate cryptic
SM-BGCs in Streptomyces [87, 89, 90, 93]. For example,
oxytetracycline production was increased in S. rimosus by
deleting zwf2 and devB, and redirecting oxygen and
NADPH to oxytetracycline biosynthesis [93]. In addition,
knock-in of a strong promoter upstream of pathway-
specific transcriptional activators or secondary metabolite
biosynthesis genes increased secondary metabolite
production and activated silent SM-BGCs [87]. 
In addition to the in vivo genome engineering, CRISPR/
Cas9 can be utilized for cloning and refactoring of large
SM-BGCs [89, 95-99]. Restriction enzymes or PCR-based
cloning strategies are not suitable for manipulation of
large-sized DNA fragments due to the limited restriction
sites and DNA amplification errors. The high-resolution
site-specific cleavage activity of the CRISPR/Cas9 system
enables efficient in vitro manipulation of large SM-BGCs,
up to 100 kb [96]. In addition, multiplexed refactoring of
promoters in a SM-BGC has been facilitated by using a
CRISPR/Cas9 system with transformation-associated recom-
bination (TAR) in yeast [97]. Therefore, these in vitro SM-
BGC engineering tools will provide an efficient strategy for
cloning and repurposing SM-BGCs to enhance secondary
metabolite production and activate silent SM-BGCs.
CRISPR/Cas9-Based Transcriptional Repression and
Activation
Cas9 contains two nuclease domains, RuvC1 and HNH,
which are responsible for DSB formation at the target DNA
sequence [79]. Introduction of two silencing mutations to
the RuvC1 and HNH nuclease domains (D10A and H840A)
generates catalytically dead Cas9 (dCas9), which lacks
nuclease activity yet retains DNA binding activity. By
guiding dCas9 to the promoter region or coding region of
the target gene, transcription initiation or transcription
elongation can be blocked, respectively [100]. The CRISPR/
dCas9-based transcriptional repression system, called
CRISPR interference (CRISPRi), has been exploited for
transcriptional repression of genes in S. coelicolor [86, 101].
Further, transcriptional repression of genes within SM-
BGC by the CRISPRi resulted in decreased production of
secondary metabolites [86, 101]. In addition, transcriptional
repression by CRISPRi system can be utilized to screen
functional genes [101]. Although a high-throughput functional
gene screening system based on transposon sequencing
(Tn-seq) has been implemented in Streptomyces, the
674 Lee et al.
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Table 2. Application of CRISPR/Cas9-mediated engineering in Streptomyces.
Cas Target Strategy Vector Repair Organism
Related secondary 
metabolite
Remark Ref
SpCas9 actI-orf1 Disruption pCRISPR-Cas9 NHEJ S. coelicolor ACT Reconstituted NHEJ with 
ligD expression
[86]
actVB Disruption pCRISPR-Cas9 NHEJ S. coelicolor ACT Reconstituted NHEJ with 
ligD expression
actI-orf2 Disruption pWHU NHEJ S. coelicolor ACT codA(sm)-based 
screening system for 
plasmid-cured strain
[88]
zwf2 Disruption pCRISPomyces NHEJ S. rimosus - Oxytetracycline 
production enhancement 
by disruption of 
competitive gene
[93]
devB Disruption pCRISPomyces NHEJ S. rimosus - Oxytetracycline 
production enhancement 
by disruption of 
competitive gene
sshg_00040 - sshg_00050 Deletion pCRISPomyces HDR S. albus Lanthipeptide - [50]
sshg_05713 Deletion pCRISPomyces HDR S. albus Polycylic tetramic 
acid macrolactam
-
Formicamycin cluster Deletion pCRISPomyces HDR S. formicae Formicamycin - [91]
forV Deletion pCRISPomyces HDR S. formicae Formicamycin -
actVA-orf5 Deletion pCRISPomyces HDR S. lividans ACT - [50]
redD - redF Deletion pCRISPomyces HDR S. lividans RED -
redN Deletion pCRISPomyces HDR S. lividans RED -
actVA-orf5 and redN Deletion pCRISPomyces HDR S. lividans ACT and RED Multiplexed editing
devB Deletion pCRISPomyces HDR S. rimosus - Oxytetracycline 
production enhancement 
by disruption of 
competitive gene
[93]
zwf2 Deletion pCRISPomyces HDR S. rimosus - Oxytetracycline 
production enhancement 
by disruption of 
competitive gene
phpD Deletion pCRISPomyces HDR S. viridochromogenes Phosphinothricin 
tripeptide
- [50]
phpM Deletion pCRISPomyces HDR S. viridochromogenes Phosphinothricin 
tripeptide
-
sceN Deletion pCRISPR-Cas9 HDR Streptomyces 
sp.SD85
BGC11 
(sceliphrolactam)
- [18]
sceQ-sceR fusion Deletion pCRISPR-Cas9 HDR Streptomyces 
sp.SD85
BGC11 
(sceliphrolactam)
Fusion of sceQ and sce R 
by deleting stop codon of 
sceQ, intergenic region 
between sceQ and sceR, 
and start codon of sceR
actI-orf1 Deletion pCRISPR-Cas9 HDR S. coelicolor ACT - [86]
actVB Deletion pCRISPR-Cas9 HDR S. coelicolor ACT -
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Table 2. Continued.
Cas Target Strategy Vector Repair Organism
Related secondary 
metabolite
Remark Ref
SpCas9 ACT cluster Deletion pKCCas9 HDR S. coelicolor ACT - [42]
actII-orf4 Deletion pKCCas9 HDR S. coelicolor ACT -
actII-orf4 and redD Deletion pKCCas9 HDR S. coelicolor ACT and RED Multiplexed editing
CDA cluster Deletion pKCCas9 HDR S. coelicolor CDA -
glnR Deletion pKCCas9 HDR S. coelicolor - -
RED cluster Deletion pKCCas9 HDR S. coelicolor RED -
redD Deletion pKCCas9 HDR S. coelicolor RED -
papR3 Deletion pKCCas9 HDR S. pristinaespiralis pristinamycin - [90]
snaE1 and snaE2 Deletion pKCCas9 HDR S. pristinaespiralis pristinamycin -
actI-orf2 Deletion pWHU HDR S. coelicolor ACT Development of 
codA(sm)-based 
selection system for 
screening plasmid-cured 
strain
[88]
rpsL Point 
mutation
pKCCas9 HDR S. coelicolor - Lys88Glu mutation [42]
ACT, CDA,
CPK, RED
deleted region
Replacement pKCCas9 HDR S. coelicolor M1146, 
M1152
- ΦC31 attB integration [89]
Non-target
BGCs
Replacement pKCCas9 HDR S. pristinaespiralis BGC2, 3, 5, 13, and 
15
Non-target BGC 
replacement with ΦC31 
attB or ΦBT1 attB site
indC-like indigoidine 
synthase
Insertion pCRISPomyces HDR S. albus Indigoidine KasO* promoter knock-in 
to activate silent BGCs
[87]
redD Insertion pCRISPomyces HDR S. lividans RED KasO* promoter knock-in 
to activate silent BGCs
actII-orf4 Insertion pCRISPomyces HDR S. lividans ACT KasO* promoter knock-in 
to activate silent BGCs
frbD operon
and frbC
homolog
Insertion pCRISPomyces HDR S. roseosporus FR-900098 KasO* promoter knock-in 
to activate silent BGCs
main synthase gene Insertion pCRISPomyces HDR S. roseosporus BGC3 (T1pks) KasO* promoter knock-in 
to activate silent BGCs
luxR-type regulator Insertion pCRISPomyces HDR S. roseosporus BGC18 (T1pks) KasO* promoter knock-in 
to activate silent BGCs
SSGG_RS0133915 Insertion pCRISPomyces HDR S. roseosporus BGC24
(Nrps-t1pks)
KasO* promoter knock-in 
to activate silent BGCs
rppA
and cytochrome P450
Insertion pCRISPomyces HDR S. venezuelae BGC16 (T3pks) KasO* promoter knock-in 
to activate silent BGCs
SSQG_RS26895-RS26920 
operon
Insertion pCRISPomyces HDR S. viridochromogenes BGC22 (T2pks) KasO* promoter knock-in 
to activate silent BGCs
rkD Cloning - - - RK-682 ICE [95]
homE Cloning - - - Holomycin ICE
stuE~stuF2 Cloning - - - Tü 3010 ICE [98]
stuD1, stuD2 Cloning - - - Tü 3010 ICE
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Table 2. Continued.
Cas Target Strategy Vector Repair Organism
Related secondary 
metabolite
Remark Ref
SpCas9 Tetarimycin BGC Cloning - - - Tetarimycin mCRISTAR [97]
spr1 region
(pglE - snbC)
Cloning - - - Pristinamycin mCRISTAR [90]
5-oxomilbemycin BGC Cloning - - - 5-oxomilbemycin mCRISTAR [99]
Jadomycin and 
chlortetracycline BGC
Cloning - - - Jadomycin, and 
chlortetracycline
CATCH [96]
Chloramphenicol, YM-
216391, and pristinamycin 
II BGCs
Cloning - - - Chloramphenicol, 
YM-216391, and 
pristinamycin
CRISPR/Cas9 cleavage 
and Gibson assembly
[89]
SpdCas9 actI-orf1 CRISPRi pCRISPR-dCas9 - S. coelicolor ACT - [86]
actI-orf1 CRISPRi pSET-dCas9 - S. coelicolor ACT - [101]
actII-orf4 CRISPRi pSET-dCas9 - S. coelicolor ACT -
cdaPS1 CRISPRi pSET-dCas9 - S. coelicolor CDA -
cpkA CRISPRi pSET-dCas9 - S. coelicolor CPK -
redQ CRISPRi pSET-dCas9 - S. coelicolor RED -
actI-orf1 and cdaPS1 CRISPRi pSET-dCas9 - S. coelicolor ACT, CDA Multiplexed editing
actI-orf1 and 
cdaPS1, cpkA
CRISPRi pSET-dCas9 - S. coelicolor ACT, CDA, and 
CPK
Multiplexed editing
actI-orf1, cdaPS1, and 
cpkA, redQ
CRISPRi pSET-dCas9 - S. coelicolor ACT, RED, CDA, 
and CPK
Multiplexed editing
Proteins with AmiR and 
NasR Transcriptional 
Antiterminator Regulator 
domain (ANTAR)
CRISPRi pSET-dCas9 - S. coelicolor - Gene essentiality test
FnCpf1 actI-orf1 Disruption pKCCpf1 NHEJ S. coelicolor ACT - [106]
actI-orf1 Disruption pKCCpf1 NHEJ S. coelicolor ACT Reconstituted NHEJ with 
ligD and Ku expression
redX Disruption pKCCpf1 NHEJ S. coelicolor RED -
redX Disruption pKCCpf1 NHEJ S. coelicolor RED Reconstituted NHEJ with 
ligD and Ku expression
redX, redG Deletion pKCCpf1 NHEJ S. coelicolor RED Deletion by reconstituted 
NHEJ with ligD and Ku 
expression at two 
cleavage sites
actI-orfI Deletion pKCCpf1 HDR S. coelicolor ACT -
redX Deletion pKCCpf1 HDR S. coelicolor RED -
actI-orf1, redX Deletion pKCCpf1 HDR S. coelicolor ACT and RED Multiplexed editing
SBI00792 Deletion pKCCpf1 HDR S. hygroscopicus Adjacent to 
5-oxomilbemycin
-
FnddCpf1
actI-orf1 CRISPRi pSETddCpf1 - S. coelicolor ACT -
redX CRISPRi pSETddCpf1 - S. coelicolor RED -
cpkA CRISPRi pSETddCpf1 - S. coelicolor CPK -
redX, actI-orf1, 
and cpkA
CRISPRi pSETddCpf1 - S. coelicolor RED, ACT, 
and CPK
Multiplexed editing
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resolution of Tn mutagenesis is relatively low, and thus
insufficient for screening of essential Streptomyces genes
[102]. The CRISPRi-based screening will enable high-
throughput identification of essential genes and provide
invaluable resources for the construction of genome-
reduced chassis for efficient production of secondary
metabolites via heterologous expression [103, 104].
Cpf1 as an Alternative to Cas9
Since SpCas9 recognizes 5’-NGG as the PAM sequence,
there are considerable target sites in the GC-rich Streptomyces
genome [85]. However, AT-rich regions in the Streptomyces
genome are not targetable by the CRISPR/SpCas9 system,
limiting precise engineering of the desired genomic locus.
To overcome this limitation, another Cas enzyme from
Francisella novicida, FnCpf1, has been introduced to
Streptomyces as an alternative genome engineering tool.
FnCpf1 recognizes 5’-TTV as the PAM sequence, and thus
is suitable for targeting AT-rich regions, further elevating
the potential of CRISPR/Cas-based genome engineering in
Streptomyces [105]. Based on CRISPR/Cpf1, successful
applications, including NHEJ, reconstituted NHEJ and HDR-
mediated genome editing, have been made in Streptomyces
[106]. In addition to genome editing, transcriptional
repression based on DNase-deactivated Cpf1 (ddCpf1) has
been applied in Streptomyces, successfully covering all
applications of CRISPR/Cas9 for Streptomyces [106]. Cpf1
not only expands the potential targets for CRISPR/Cas
mediated genome engineering, but it also broadens the
range of CRISPR/Cas applicable organisms with less
cellular toxicity compared to Cas9 [106]. However, in vitro
applications of the CRISPR/Cpf1 system have not been
described for SM-BGC cloning in Streptomyces. Unlike
Cas9, Cpf1 generates a DSB with sticky ends, which may
enable efficient directional cloning with simple ligation
[105].
Heterologous Expression of Secondary Metabolite
Biosynthetic Gene Clusters
Compared to secondary metabolite production in the
native host, heterologous expression has several advantages,
including: (1) it enables SM-BGCs expression of unculturable
or slow-growing native host strains, (2) it overcomes the
difficult genetic manipulation of the native host, and (3) it
bypasses the innate regulatory network of the native host
[107]. In fact, the Streptomyces species is the most suitable
host for heterologous expression of SM-BGCs, as compared
to other organisms such as E. coli, bacillus, or yeast, because
of its (1) abundant precursors, cofactors, and enzymes for
secondary metabolite biosynthesis; (2) sophisticated post-
modification system for secondary metabolites such as
phosphorylation, acetylation, farnesylation, and glycosylation;
(3) broad antibiotic resistance and tolerance; (4) proper
protein folding for the functionality of multi-enzyme
complexes; and (5) other cellular environments, including
pH and redox potential [108]. Over the past few decades,
approximately 100 SM-BGCs have been heterologously
expressed in Streptomyces, particularly in S. coelicolor,
S. lividans, S. avermitilis, and S. albus [109]. Although
heterologous expression has been successfully used for
secondary metabolite production, several limitations still
remain. First, the large size of SM-BGC hampers the
efficiency of genetic manipulation [110]. Further, even if
the transfer of SM-BGCs to the heterologous expression
host was successful, their expression may be insignificant
due to differences in the precursor pool from that of the
native host and metabolic competitions between the target
SM-BGC and other endogenous SM-BGCs in the expression
host [108]. In this subsection, we discuss cloning strategies
for large-size SM-BGCs and optimization of the heterologous
expression host.
There are four steps to express the SM-BGC in the
heterologous expression host, which include (1) acquisition
of the target SM-BGC from the native host genome, (2)
ligation or assembly of the SM-BGC to the vector, (3)
transfer of the SM-BGC-encoded vector to the heterologous
expression host, and (4) target of secondary metabolite
production (Table 3). 
The most frequently used method for acquisition of the
target SM-BGC is the genomic library construction using
cosmid, fosmid, BAC, and PAC vectors [109]. This method
can be applied to a broad range of Streptomyces genomes, in
which the full sequence is unknown. It is particularly
effective to discover novel secondary metabolites from the
metagenome, including unculturable bacteria [111]. The
second method is to cut both ends of the target SM-BGC
from the genomic DNA. However, restriction sites are not
generally available at both ends of target SM-BGCs. Thus,
unique restriction sites can be introduced using a suicide
plasmid, which contains a homologous sequence of one of
the end sites, and integrated into both ends of target SM-
BGCs by single crossover. Streptomyces bacterial artificial
chromosome system (pSBAC) is a successful example for
some SM-BGCs, such as tautomycetin (80 kb) and pikromycin
(60 kb) [112, 113]. Another strategy is the integrase-mediated
recombination (IR) system that introduces integration sites,
such as attB
6
 and attB
9
, at both ends by single crossover
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homologous recombination of the vector, such as pKC1139
[114]. Φ-integrase-mediated excision of the target SM-BGC
is subsequently performed to obtain the SM-BGC vector in
vivo. Recently, in vitro site-specific digestion of genomic
DNA using the CRISPR/Cas9 system was used as an
alternative strategy for the acquisition of target SM-BGCs
[94-97, 115]. The third method for acquisition of target SM-
BGCs is PCR amplification [116], in which each fragment
has homologous arms at both ends added by PCR primers
to self-assemble or assemble together with genetic parts such
as promoters and RBSs. As all three SM-BGC acquisition
methods have their own advantages and limitations, they
should be applied according to specific situations.
Ligation or assembly methods of target SM-BGC to the
heterologous expression vector can be largely divided into
two groups, in vitro and in vivo. In vitro cloning of the
target SM-BGCs involves (1) ligation of cognate sticky ends
formed by restriction enzyme digestion or two CRISPR/
Cas9 digestion using T4 DNA ligase [95, 109] and (2)
Gibson assembly using 5’ exonuclease [89, 96]. Ligation of
two fragments by DNA ligase is simple and efficient, but
preparation of cognate ends for ligation is required.
Conversely, the Gibson assembly method is theoretically
universal for any fragments by introduction of homologous
sequence at their ends through PCR amplification. In vivo
cloning of SM-BGCs exploits the homologous recombination
system in the native host [114], E. coli [117], and yeast [118].
For example, integrase-mediated recombination (IR) directly
obtains the SM-BGC-containing vector from the genomic
DNA of the native host [114]. Linear-linear homologous
recombination (LLHR) using λ-Red system or RecET
system in E. coli is one of the most widely used in vivo
recombination systems with high cloning efficiency, but
their reported size limit is about 50 kb [107, 109, 117].
Unlike bacteria, yeast have their own efficient homologous
recombination system, such that more than two large
fragments can be assembled by transformation of all
fragments simultaneously into yeast, which is named as
transformation-associated recombination (TAR) [119]. The
TAR cloning method has shown relatively higher efficiency,
size capacity, and number of fragments in many strategies
such as CRISPR-TAR, mCRISTAR, and DNA assembler,
compared to other in vivo cloning methods [97, 116, 120].
Thus, TAR and in vitro Gibson assembly are considered as
the most high-throughput and efficient strategies for the
preparation of Streptomyces SM-BGCs vectors.
In most cases, constructed SM-BGC vectors have been
transformed to the heterologous expression host through
conjugation between E. coli and Streptomyces strains [109].
Otherwise, the vector can be directly transformed to the
heterologous expression host by the protoplast method
[32], which depends on the vector components such as oriT
(essential for conjugation) and the Streptomyces species.
After transfer of the SM-BGC vector to the expression host,
the SM-BGC vector can be integrated into the host genome
or remain as a replicative plasmid. Most heterologous
Table 3. Different strategy for BGC cloning.
BGC cloning steps Strategies Representative examples Ref
Acquisition of the target BGC 
from the native host genome
Genomic library Cosmid, fosmid, BAC, and PAC [135]
Cut off both ends 
of target BGC 
Restriction: pSBAC [113]
Integrase: IR [114]
CRISPR: CATCH, mCRISTAR, and CRISPR-TAR [96, 97, 120]
PCR amplification DNA assembler [116]
Ligation or assembly of the 
target BGC to the vector
In vitro Sticky end ligation: pSBAC [113]
Blunt end ligation: ICE [95]
Gibson assembly: CATCH and MSGE [89, 96]
In vivo Recombination in native host: IR [114]
Recombination in E. coli: LLHR [117]
Recombination in yeast: TAR, DNA assembler, 
DiPac, and mCRISTAR
[97, 115, 116, 
118]
Transferring BGC vector to the 
expression host
Conjugation pUWLcre [136]
Protoplast transformation pSKC2 and pOJ446 [137]
Target secondary metabolite production 
by expression of the BGC vector
Integrative pSET152, pCAP01, and pESAC [118, 138]
Replicative pSKC2 and pUWL201 [139]
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expression vectors in previous studies were integrative
vectors, which are more stable after serial generations
[109]. Genetic stability is very important for the further
fermentation process of secondary metabolites [121].
However, the copy number of the integrative SM-BGC
vector is only one compared to multi-copy replicative
vectors. Therefore, multi-copy integration of the SM-BGC
vector into genome or promoter refactoring of SM-BGC genes
should be additionally performed to increase productivity
[89]. Thus far, many SM-BGC cloning strategies for
heterologous expression have been developed. However,
cloning of a large size and number of SM-BGC fragments is
a common limitation. Therefore, a high-throughput, stepwise,
systematic strategy for efficient cloning of SM-BGCs for
heterologous expression should be considered.
Streptomyces Chassis Strains for Heterologous
Gene Expression 
To improve yields of secondary metabolites, Streptomyces
hosts were genetically modified by removing endogenous
SM-BGCs, nonessential genes, and genomic regions and
engineering genes with pleiotropic functions. Representative
examples of optimized Streptomyces as heterologous
expression hosts are shown in Table 4. Removing SM-BGCs
resulted in a “reduced Streptomyces genome,” which can
conserve energy and other building blocks in addition to
the specific precursor pool. In other words, the nucleotide
and energy for replication of the reduced genome will be
decreased, and this redundant energy can be used for the
target metabolite production. Indeed, several engineered
strains of S. coelicolor (4 SM-BGCs deletion), S. lividans (3
SM-BGCs deletion), and S. albus (15 SM-BGCs deletion)
have shown improved target secondary metabolite
production and reduced background chemical profiles
[104, 122-124].
Nonessential genomic regions (NGR) are usually located
at the ends of linear chromosomes, which are not conserved
in all species and dispensable for cell growth. They include
genomic islands (GI), IS elements, and endogenous CRISPR
array regions that decrease genomic stability. For example,
NGRs in S. avermitilis (1.48 Mb) and S. chattanoogenisis
(0.7 Mb) were selected, based on comparative genomics of
Streptomyces genomes, and deleted by λ-Red system or
Cre/loxP recombination system [121, 125]. As expected,
deletion of NGRs increased the fitness level of the engineered
strain relative to the wild-type strain with beneficial effects
on morphology, ATP level, NADPH level, transformation
efficiency, and genetic stability in S. chattanoogenisis [121].
However, large deletion of NGRs may cause undesired
deleterious effects on cell growth due to the unknown
essential function of genes and synthetic lethality of more
than two abundant essential genes. Therefore, the systems
level of functional genomic studies should be followed to
determine the nonessential regions more precisely.
Integration of these functional studies with multi-omics data
and experimental validations might allow construction of a
highly efficient Streptomyces chassis strain for heterologous
expression of SM-BGCs [126, 127].
Genes with pleiotropic functions can be additionally
engineered to improve productivity of target secondary
metabolites. For instance, deletion of phosphofructokinase
gene pfk and global transcriptional regulator gene wblA and
overexpression of global transcriptional regulator gene crp
in S. albus increased secondary metabolite production,
redox potential, and fitness by changing the global
transcriptional status [128]. Further, point mutations of
RNA polymerase gene rpoB and ribosomal protein gene
rpsL in S. coelicolor showed increased fitness and secondary
metabolite production by altering regulation at both the
transcriptional and translational levels [104]. As pleiotropic
functions usually include undesired phenotypes for
secondary metabolite production, the engineering target
should be selected carefully through rational design based
on systematic information.
Future Perspective
In this review, we summarized a synthetic biology strategy
to produce novel secondary metabolites in Streptomyces.
Accumulation of genetic information and SM-BGCs aided
by recent advances in Next-Generation Sequencing (NGS)
has revealed the enormous potential of Streptomyces as a
reservoir for novel bioactive compounds and is far
outpacing our capacity to explore SM-BGCs and their
products [129]. To fully harness Streptomyces’ ability to
produce valuable secondary metabolites, rational design
and efficient synthetic biology tools for Streptomyces are
essential. To date, however, in silico SM-BGC prediction
tools, such as antiSMASH, still need to be optimized for
precise mining capability. Further, synthetic biology tools
for Streptomyces are limited to fulfill the precise designs for
novel secondary metabolite production. To this end,
integration of massive omics data and vigorous functional
studies can elevate the fidelity of SM-BGC mining and
increase genetic parts for Streptomyces engineering.
Specifically, construction of genetic part libraries based on
transcriptome and translatome data by screening using a
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Table 4. Representative examples of Streptomyces chassis strain for optimal heterologous expression.
Heterologous 
host
Engineering
Target genes 
or regions
Deletion method Expressed BGC BGC vector Effect Limitation Ref
Streptomyces 
coelicolor 
M145
BGC 
deletion and 
Pleiotropic 
gene 
engineering
Deletion of four 
BGCs (ACT, RED, 
CPK, and CDA) 
Point mutations of 
rpoB and rpsL.
Homologous 
recombination by 
double crossover of 
the plasmid
Shlorampheniocol and 
congocidine
Cosmid Improved 
production, clean 
profile of 
background 
metabolites
Low fitness [104]
Streptomyces
sp. FR-008
BGC 
deletion
Deletion of three 
BGCs (candicidin, 
type III PKS, and 
type I PKS)
Homologous 
recombination by 
double crossover of 
the plasmid
None None Improved fitness, 
sporulation, and 
clean profile of 
background 
metabolites
Heterologous 
expression was 
not tested
[124]
Streptomyces 
lividans TK24
BGC 
deletion
Deletion of three 
BGCs (ACT, RED, 
and CDA)
One copy 
integration of AfsRS 
by attB integrase
Homologous 
recombination by 
double crossover of 
the plasmid
Streptothiricins, borrelidin, 
and linear lipopeptides
BAC High-throughput 
functional genome 
mining of 
Streptomyces rochei
Low fitness, 
laborious 
screening of 
BAC libraries
[123]
Streptomyces 
lividans TK24
BGC 
deletion
Deletion of three 
BGCs (ACT, RED, 
and CDA)
Additional copies 
integration of AfsRS 
by attB integrase
Homologous 
recombination by 
double crossover of 
the plasmid
Hybrubins BAC High-throughput 
functional genome 
mining of 
Streptomyces variabilis 
Pathway crosstalk 
between 
incompletely deleted 
RED cluster.
Low fitness [140]
Streptomyces 
albus J1074
BGC 
deletion
Deletion of fifteen 
BGCs (Frontalamide, 
Paulomycin, 
Geosmin, 
Lantibiotic, 
carotenoid, flaviolin, 
candicidin, 
antimycin, 2 PKS-
NRPS, and 4 NRPS)
Homologous 
recombination by 
double crossover of 
the plasmid using 
λ-red system
Tunicamycin B2, 
moenomycin M,
griseorhodin A,
pyridinopyrone A,
bhimamycin A, 
didesmethylmensacarcin, 
didemethoxyaranciamycino
ne, aloesaponarin II, and
cinnamycin, fralnimycin
Fosmid 
and BAC
Improved 
production, clean 
profile of 
background 
metabolites
Moenomycin M 
productivity 
was reduced.
[122]
Streptomyces 
avermitilis
Nonessential 
region 
deletion 
and BGC 
deletion
Deletion of 1.48 Mb 
left arm determined 
by comparative 
genomics
Homologous 
recombination by 
double crossover of 
the plasmid using 
λ-red system
Cre/loxP system
Streptomycin, cephamycin 
C, and pladienolide
Cosmidand 
BAC
Improved 
production by 
additional 
introduction of 
regulatory gene and 
optimization of 
codon usage
Low 
conjugation 
efficiency
[103]
Streptomyces 
avermitilis
Nonessential 
region 
deletion
Deletion of 1.48 Mb 
left arm and some 
regions determined 
by comparative 
genomics
Homologous 
recombination by 
double crossover of 
the plasmid using 
λ-red system
Cre/loxP system
Streptomycin, ribostamycin, 
kasugamycin, pholipomycin, 
oxytetracycline, 
resistomycin, pladienolide B, 
erythromycin A,
bafilimycin B1, nemadectin α, 
aureothin, leptomycin, 
cephamycin C, holomycin, 
lactacystin, clavulanic acid, 
rebeccamycin, novobiocin, 
chloramphenicol,
2-methylisoborneol, 
pentalenolactone,
amorpha-1,4-diene,
taxa-4,11-diene, 
levopimaradiene, and 
abietatriene
Cosmid 
and BAC
Improved 
production, fitness, 
clean profile of 
background 
metabolites. Broad 
precursor capacity 
(sugar, polyketide, 
peptide, shikimate, 
and MVA or MEP)
Ribostamycin, 
oxytetracycline 
productivity 
were reduced
[125]
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high-throughput reporter system will deliver a universal
set of genetic parts for Streptomyces. 
Although genetic tools based on the CRISPR/Cas system
have offered diverse strategies to enhance secondary
metabolite production and activate silent SM-BGCs [87, 89,
90, 93, 99], further optimization of the CRISPR/Cas system
for Streptomyces is still required. An example is that the
toxicity of Cas nucleases is disadvantageous for multiplexed
applications and CRISPR/Cas bearing systems. In addition,
expansion of PAM recognition is required to enable
efficient genome engineering. These limitations can be
overcome by modulating Cas expression and exploiting
Cas variants [106, 130, 131]. Particularly, CRISPR activation
(CRISPRa) has not been applied to Streptomyces [132]. The
CRISPRa approach can serve as an efficient strategy to
investigate silent SM-BGCs without labor-intensive genome
editing efforts. Multiplexing the precise transcriptional
regulation through integration of both CRISPRa and
CRISPRi is expected to reconstruct the metabolic network
to enhance the precursor supply, reducing flux toward
competing pathways or unwanted by-products, bypassing
gene expression regulation, and expressing the SM-BGCs.
Recently, toehold-gated gRNA was developed, which links
endogenous signals to activation of the CRISPR/Cas
system [133]. As the production of secondary metabolites
requires sufficient accumulation of precursors and activation
of biosynthetic genes, the combination of toehold-gated
gRNA and CRISPRa and CRISPRi strategies will suggest a
new metabolic engineering approach, linking the production
of precursors to production of secondary metabolites. 
Development of synthetic biology tools can also be
exploited to construct the Streptomyces chassis for
heterologous expression of novel SM-BGCs. So far, S. albus
J1074 with deletion of 15 BGCs and S. chattanoogensis L10
with deletion of 0.7 Mb of a nonessential arm seem to be
the best Streptomyces chassis for heterologous expression
[121, 122]. A further challenge might be the construction of
the “superhost Streptomyces chassis” by removing all
endogenous SM-BGCs, nonessential genes, and genomic
regions and adding all precursor synthetic genes. By
heterologous expression of the target SM-BGC in this
superhost chassis, productivity of target secondary
metabolites will be further improved. In addition, novel
secondary metabolites will be discovered from a wide
array of silent SM-BGCs in a high-throughput manner.
However, construction of a superhost for all secondary
metabolites might not be feasible due to precursor
differences in Streptomyces species. Indeed, all five types of
secondary metabolites were produced in the S. albus J1074
strain; however, some metabolites were not produced
significantly [122]. Therefore, construction of several
“specialized Streptomyces chassis hosts” for each type of
secondary metabolite might be a better choice [108]. This
“design-build-test (DBT)” cycle, which is a rational design
based on in silico SM-BGC mining, the build of a SM-BGC
expression in Streptomyces chassis, and the high-throughput
test of secondary metabolite production will be iterated to
learn and optimize production of novel secondary metabolites
(Fig. 1). This synthetic biology strategy will ultimately
expand the productivity and diversity of available novel
secondary metabolites as potential biopharmaceuticals.
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Table 4. Continued.
Heterologous 
host
Engineering
Target genes 
or regions
Deletion method Expressed BGC BGC vector Effect Limitation Ref
Streptomyces 
chattanoogensis 
L10
Nonessential 
region 
deletion
Deletion of 1.3 Mb 
and 0.7 Mb 
nonessential arms 
determined by 
comparative 
genomics and 
prediction tools
Cre/loxP 
recombination
ACT pMM1 Improved 
production, fitness, 
ATP, NADPH, 
transformation 
efficiency, and 
genetic stability. 
Dispersed 
morphology.
1.3 Mb deleted 
strain was 
detrimental 
due to deletion 
of some 
unknown genes
[121]
Streptomyces 
albus J1074
Pleiotropic 
gene 
engineering 
and BGC 
deletion
Deletion of pfk, wblA, 
overexpression of 
cpk, and deletion of 
one BGC 
(paulomycin)
Homologous 
recombination by 
double crossover of 
the plasmid using 
λ-red system
ACT Fosmid Improved 
production, fitness, 
and NADPH.
Undesirable 
effects might be 
incurred due to 
the global 
change of 
transcriptome
[128]
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